(Q43734597)

26 November 2017

title

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism (English)

1 reference

Helicobacter pylori infectious disease

26 November 2017

0 references

0 references

1 reference

K Hokari

1

1 reference

26 November 2017

T Sugiyama

2

1 reference

26 November 2017

M Kato

3

1 reference

26 November 2017

M Saito

4

1 reference

26 November 2017

T Miyagishima

5

1 reference

26 November 2017

M Kudo

6

1 reference

26 November 2017

K Nishikawa

7

1 reference

26 November 2017

J Ishizuka

8

1 reference

26 November 2017

Y Komatsu

9

1 reference

26 November 2017

T Mizushima

10

1 reference

26 November 2017

H Kagaya

11

1 reference

26 November 2017

S Hige

12

1 reference

26 November 2017

H Takeda

13

1 reference

26 November 2017

M Asaka

14

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Alimentary Pharmacology & Therapeutics

26 November 2017

published in

1 reference

26 November 2017

volume

15

1 reference

26 November 2017

issue

9

1 reference

26 November 2017

page(s)

1479-1484

1 reference

Chronic gastritis--a pathogenetic approach

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Suppressive effect of ethanol on the expression of hepatic asialoglycoprotein receptors augmented by interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Biochemistry and molecular biology of the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

An international association between Helicobacter pylori infection and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01063.X

10.1046/J.1365-2036.2001.01063.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference